Literature DB >> 18978480

Slow efavirenz metabolism genotype is common in Botswana.

Robert Gross, Richard Aplenc, Thomas Tenhave, Andrea S Foulkes, Rameshwari Thakur, Mosepele Mosepele, Jeffrey S Barrett, Charles Flexner, Brian L Strom, Gregory Bisson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18978480      PMCID： PMC5070462          DOI： 10.1097/QAI.0b013e31817c1ed0

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  15 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

2.  A comparison of bayesian methods for haplotype reconstruction from population genotype data.

Authors:  Matthew Stephens; Peter Donnelly
Journal:  Am J Hum Genet       Date:  2003-10-20       Impact factor: 11.025

3.  Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.

Authors:  Heather J Ribaudo; David W Haas; Camlin Tierney; Richard B Kim; Grant R Wilkinson; Roy M Gulick; David B Clifford; Catia Marzolini; Courtney V Fletcher; Karen T Tashima; Daniel R Kuritzkes; Edward P Acosta
Journal:  Clin Infect Dis       Date:  2005-12-27       Impact factor: 9.079

4.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Authors:  David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta
Journal:  AIDS       Date:  2004-12-03       Impact factor: 4.177

5.  Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.

Authors:  Sonia Rodriguez-Novoa; Pablo Barreiro; Ana Rendón; Inmaculada Jiménez-Nacher; Juan González-Lahoz; Vincent Soriano
Journal:  Clin Infect Dis       Date:  2005-03-31       Impact factor: 9.079

6.  Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.

Authors:  Akihiko Saitoh; Courtney V Fletcher; Richard Brundage; Carmelita Alvero; Terrence Fenton; Karen Hsia; Stephen A Spector
Journal:  J Acquir Immune Defic Syndr       Date:  2007-07-01       Impact factor: 3.731

7.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.

Authors:  Margalida Rotger; Sara Colombo; Hansjakob Furrer; Gabriela Bleiber; Thierry Buclin; Belle L Lee; Olivia Keiser; Jérôme Biollaz; Laurent Décosterd; Amalio Telenti
Journal:  Pharmacogenet Genomics       Date:  2005-01       Impact factor: 2.089

8.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

9.  Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Authors:  David W Haas; Laura M Smeaton; Robert W Shafer; Gregory K Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victor De Gruttola; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; Alfred L George; John P Donahue; Richard B Kim
Journal:  J Infect Dis       Date:  2005-11-01       Impact factor: 5.226

10.  Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

Authors:  Hiroyuki Gatanaga; Tsunefusa Hayashida; Kiyoto Tsuchiya; Munehiro Yoshino; Takeshi Kuwahara; Hiroki Tsukada; Katsuya Fujimoto; Isao Sato; Mikio Ueda; Masahide Horiba; Motohiro Hamaguchi; Masahiro Yamamoto; Noboru Takata; Akiro Kimura; Takao Koike; Fumitake Gejyo; Shuzo Matsushita; Takuma Shirasaka; Satoshi Kimura; Shinichi Oka
Journal:  Clin Infect Dis       Date:  2007-09-24       Impact factor: 9.079
View more
  22 in total

1.  Patterns of HIV Treatment Adherence do not Differ Between Male and Female Adolescents in Botswana.

Authors:  Kimon L H Ioannides; Jennifer Chapman; Tafireyi Marukutira; Ontibile Tshume; Gabriel Anabwani; Robert Gross; Elizabeth D Lowenthal
Journal:  AIDS Behav       Date:  2017-02

Review 2.  African genetic diversity and adaptation inform a precision medicine agenda.

Authors:  Luisa Pereira; Leon Mutesa; Paulina Tindana; Michèle Ramsay
Journal:  Nat Rev Genet       Date:  2021-01-11       Impact factor: 53.242

3.  CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.

Authors:  Robert Gross; Scarlett L Bellamy; Bakgaki Ratshaa; Xiaoyan Han; Marijana Vujkovic; Richard Aplenc; Andrew P Steenhoff; Mosepele Mosepele; Ganesh Moorthy; Athena F Zuppa; Brian L Strom; Gregory P Bisson
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

4.  Gynaecomastia in two men on stable antiretroviral therapy who commenced treatment for tuberculosis.

Authors:  Jeremy D Kratz; Ahmad Y El-Shazly; Santos G Mambuque; Elpidio Demetria; Peter Veldkamp; Timothy S Anderson
Journal:  Malawi Med J       Date:  2016-12       Impact factor: 0.875

5.  Frequent malaria illness episodes in two Malawian patients on antiretroviral therapy soon after stopping cotrimoxazole preventive therapy.

Authors:  Wongani Js Nyangulu; Edson Mwinjiwa; Titus H Divala; Randy G Mungwira; Osward Nyirenda; Maxwell Kanjala; Gillian Mbambo; Jane Mallewa; Terrie E Taylor; Matthew B Laurens; Miriam K Laufer; Joep J van Oosterhout
Journal:  Malawi Med J       Date:  2017-03       Impact factor: 0.875

Review 6.  Efavirenz in the therapy of HIV infection.

Authors:  Natella Y Rakhmanina; John N van den Anker
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

7.  Effects of sex and alcohol use on antiretroviral therapy outcomes in Botswana: a cohort study.

Authors:  Robert Gross; Scarlett L Bellamy; Bakgaki Ratshaa; Xiaoyan Han; Andrew P Steenhoff; Mosepele Mosepele; Gregory P Bisson
Journal:  Addiction       Date:  2016-09-07       Impact factor: 6.526

Review 8.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

9.  Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.

Authors:  Karen Cohen; Alison Grant; Collet Dandara; Helen McIlleron; Lindiwe Pemba; Katherine Fielding; Salome Charalombous; Gavin Churchyard; Peter Smith; Gary Maartens
Journal:  Antivir Ther       Date:  2009

Review 10.  Management of individuals requiring antiretroviral therapy and TB treatment.

Authors:  Karen Cohen; Graeme Meintjes
Journal:  Curr Opin HIV AIDS       Date:  2010-01       Impact factor: 4.283
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.